Deep Learning Improves Pancreatic Cancer Diagnosis Using RNA-Based Variants
Source check: Source checked. Not independent scientific confirmation.
Finding: Deep-learning analysis of RNA-sequencing-derived variants distinguished resectable pancreatic ductal adenocarcinoma from chronic pancreatitis in a held-out cohort. Combining variant features with CA19-9 yielded a test AUC of 0.96, compared with 0.89 for variant features alone. This does not establish screening performance or clinical benefit.
Technology: Deep-learning models analyze RNA-based variant features alongside CA19-9 for pancreatic-cancer classification.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Deep-learning models analyze RNA-based variant features alongside CA19-9 for pancreatic-cancer classification.
- Test and result
- The study included 268 participants: 87 with resectable pancreatic cancer, 96 with non-resectable cancer and 85 with chronic pancreatitis. The reported combined-model test AUC for resectable cancer versus pancreatitis was 0.96.
- Limitation / still unknown
- Single-study dataset evaluation with no external prospective validation; does not establish population screening utility.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.mdpi.com/2072-6694/13/11/2654
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary source full text, including Methods and Results; first result-bearing version checked against primary publication metadata..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.